vs
爵士制药（JAZZ）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是爵士制药的1.0倍（$1.2B vs $1.2B），爵士制药净利率更高（17.0% vs 9.1%，领先7.9%），爵士制药同比增速更快（10.1% vs 5.4%），爵士制药自由现金流更多（$345.8M vs $186.5M），过去两年爵士制药的营收复合增速更高（15.2% vs 6.3%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
JAZZ vs RBA — 直观对比
营收规模更大
RBA
是对方的1.0倍
$1.2B
营收增速更快
JAZZ
高出4.7%
5.4%
净利率更高
JAZZ
高出7.9%
9.1%
自由现金流更多
JAZZ
多$159.3M
$186.5M
两年增速更快
JAZZ
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.2B |
| 净利润 | $203.5M | $109.7M |
| 毛利率 | — | — |
| 营业利润率 | 21.2% | 14.7% |
| 净利率 | 17.0% | 9.1% |
| 营收同比 | 10.1% | 5.4% |
| 净利润同比 | 6.5% | -7.4% |
| 每股收益（稀释后） | $3.34 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRBA
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $897.8M | $1.1B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $981.8M | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $902.0M | $1.1B |
净利润JAZZRBA
| Q4 25 | $203.5M | $109.7M | ||
| Q3 25 | $251.4M | $95.5M | ||
| Q2 25 | $-718.5M | $109.8M | ||
| Q1 25 | $-92.5M | $113.4M | ||
| Q4 24 | $191.1M | $118.5M | ||
| Q3 24 | $215.1M | $76.1M | ||
| Q2 24 | $168.6M | $111.1M | ||
| Q1 24 | $-14.6M | $107.4M |
营业利润率JAZZRBA
| Q4 25 | 21.2% | 14.7% | ||
| Q3 25 | 5.1% | 14.5% | ||
| Q2 25 | -65.6% | 15.9% | ||
| Q1 25 | -6.2% | 17.1% | ||
| Q4 24 | 17.5% | 18.1% | ||
| Q3 24 | 24.7% | 15.6% | ||
| Q2 24 | 19.5% | 18.4% | ||
| Q1 24 | 7.3% | 18.7% |
净利率JAZZRBA
| Q4 25 | 17.0% | 9.1% | ||
| Q3 25 | 22.3% | 8.7% | ||
| Q2 25 | -68.7% | 9.3% | ||
| Q1 25 | -10.3% | 10.2% | ||
| Q4 24 | 17.6% | 10.4% | ||
| Q3 24 | 20.4% | 7.8% | ||
| Q2 24 | 16.5% | 10.1% | ||
| Q1 24 | -1.6% | 10.1% |
每股收益（稀释后）JAZZRBA
| Q4 25 | $3.34 | $0.53 | ||
| Q3 25 | $4.08 | $0.43 | ||
| Q2 25 | $-11.74 | $0.53 | ||
| Q1 25 | $-1.52 | $0.55 | ||
| Q4 24 | $2.97 | $0.58 | ||
| Q3 24 | $3.42 | $0.36 | ||
| Q2 24 | $2.49 | $0.54 | ||
| Q1 24 | $-0.23 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $531.5M |
| 总债务越低越好 | $5.4B | $2.3B |
| 股东权益账面价值 | $4.3B | $5.6B |
| 总资产 | $11.7B | $12.1B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资JAZZRBA
| Q4 25 | $1.4B | $531.5M | ||
| Q3 25 | $1.3B | $674.7M | ||
| Q2 25 | $1.2B | $710.2M | ||
| Q1 25 | $1.9B | $578.1M | ||
| Q4 24 | $2.4B | $533.9M | ||
| Q3 24 | $2.2B | $650.7M | ||
| Q2 24 | $1.4B | $599.5M | ||
| Q1 24 | $1.4B | $462.8M |
总债务JAZZRBA
| Q4 25 | $5.4B | $2.3B | ||
| Q3 25 | $5.4B | $2.6B | ||
| Q2 25 | $5.4B | $2.6B | ||
| Q1 25 | $5.4B | $2.6B | ||
| Q4 24 | $6.1B | $2.6B | ||
| Q3 24 | $6.1B | $2.7B | ||
| Q2 24 | $5.7B | $2.8B | ||
| Q1 24 | $5.7B | $2.9B |
股东权益JAZZRBA
| Q4 25 | $4.3B | $5.6B | ||
| Q3 25 | $4.0B | $5.5B | ||
| Q2 25 | $3.7B | $5.5B | ||
| Q1 25 | $4.2B | $5.3B | ||
| Q4 24 | $4.1B | $5.2B | ||
| Q3 24 | $4.2B | $5.2B | ||
| Q2 24 | $3.8B | $5.2B | ||
| Q1 24 | $3.7B | $5.1B |
总资产JAZZRBA
| Q4 25 | $11.7B | $12.1B | ||
| Q3 25 | $11.4B | $12.2B | ||
| Q2 25 | $10.9B | $12.2B | ||
| Q1 25 | $11.5B | $11.9B | ||
| Q4 24 | $12.0B | $11.8B | ||
| Q3 24 | $12.3B | $11.9B | ||
| Q2 24 | $11.4B | $12.1B | ||
| Q1 24 | $11.3B | $12.0B |
负债/权益比JAZZRBA
| Q4 25 | 1.24× | 0.42× | ||
| Q3 25 | 1.35× | 0.47× | ||
| Q2 25 | 1.45× | 0.47× | ||
| Q1 25 | 1.29× | 0.50× | ||
| Q4 24 | 1.49× | 0.50× | ||
| Q3 24 | 1.47× | 0.52× | ||
| Q2 24 | 1.52× | 0.55× | ||
| Q1 24 | 1.54× | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $186.5M |
| 自由现金流率自由现金流/营收 | 28.9% | 15.5% |
| 资本支出强度资本支出/营收 | 1.4% | 5.7% |
| 现金转化率经营现金流/净利润 | 1.78× | 2.33× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $719.2M |
8季度趋势，按日历期对齐
经营现金流JAZZRBA
| Q4 25 | $362.5M | $255.2M | ||
| Q3 25 | $474.6M | $239.7M | ||
| Q2 25 | $88.9M | $326.5M | ||
| Q1 25 | $429.8M | $156.8M | ||
| Q4 24 | $398.6M | $184.5M | ||
| Q3 24 | $398.7M | $285.4M | ||
| Q2 24 | $331.4M | $337.3M | ||
| Q1 24 | $267.2M | $124.8M |
自由现金流JAZZRBA
| Q4 25 | $345.8M | $186.5M | ||
| Q3 25 | $459.4M | $188.5M | ||
| Q2 25 | $75.9M | $241.7M | ||
| Q1 25 | $415.9M | $102.5M | ||
| Q4 24 | $385.3M | $127.9M | ||
| Q3 24 | $388.0M | $248.5M | ||
| Q2 24 | $324.3M | $308.6M | ||
| Q1 24 | $260.3M | $79.6M |
自由现金流率JAZZRBA
| Q4 25 | 28.9% | 15.5% | ||
| Q3 25 | 40.8% | 17.3% | ||
| Q2 25 | 7.3% | 20.4% | ||
| Q1 25 | 46.3% | 9.2% | ||
| Q4 24 | 35.4% | 11.2% | ||
| Q3 24 | 36.8% | 25.3% | ||
| Q2 24 | 31.7% | 28.2% | ||
| Q1 24 | 28.9% | 7.5% |
资本支出强度JAZZRBA
| Q4 25 | 1.4% | 5.7% | ||
| Q3 25 | 1.3% | 4.7% | ||
| Q2 25 | 1.2% | 7.2% | ||
| Q1 25 | 1.5% | 4.9% | ||
| Q4 24 | 1.2% | 5.0% | ||
| Q3 24 | 1.0% | 3.8% | ||
| Q2 24 | 0.7% | 2.6% | ||
| Q1 24 | 0.8% | 4.2% |
现金转化率JAZZRBA
| Q4 25 | 1.78× | 2.33× | ||
| Q3 25 | 1.89× | 2.51× | ||
| Q2 25 | — | 2.97× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | 2.09× | 1.56× | ||
| Q3 24 | 1.85× | 3.75× | ||
| Q2 24 | 1.97× | 3.04× | ||
| Q1 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
